摘要
目的 研究对比慢性肾衰竭尿毒症期患者高通量血液透析(HFHD)、常规血液透析(HD)的治疗疗效。方法 选取2018年2月至2021年5月于北京市顺义区医院治疗的92例慢性肾衰竭尿毒症期患者的临床资料,根据透析方式的不同分为HFHD组(n=48,HFHD治疗)和HD组(n=44,HD治疗)。对比两组临床疗效、肾功能[肌酐(Cr)、尿素氮(BUN)、尿酸(SUA)]、毒素清除效果[甲状旁腺激素(PTH)、血β2微球蛋白(β2-MG),半胱氨酸蛋白酶抑制剂C(Cys C)]以及不良反应发生情况。结果 HFHD组患者临床总有效率(95.83%)高于HD组临床总有效率(81.82%),差异有统计学意义(P<0.05)。治疗后两组患者Cr、BUN、SUA均出现下降,其中以HFHD组下降更为明显,差异有统计学意义(P<0.05)。治疗后两组PTH、β2-MG、Cys C均出现下降,其中以HFHD组下降更为明显,差异有统计学意义(P<0.05)。HFHD组不良反应发生率为8.33%,低于HD组的25.00%,差异有统计学意义(P<0.05)。结论 HFHD治疗慢性肾衰竭尿毒症期患者,可有效提高临床疗效,改善患者肾功能,在减少患者体内中/大分子毒素的同时安全性较好,临床可考虑将其推广应用。
Objective To compare the therapeutic effects of high-flux hemodialysis(HFHD)and conventional hemodialysis(HD)in patients with chronic renal failure in the uremic stage. Methods The clinical data of 92 patients with chronic renal failure and uremic stage treated in Shunyi District Hospital of Beijing from February 2018 to May 2021 were selected and divided into the HFHD group(n=48,HFHD treatment)and the HD group according to different dialysis methods(n=44,HD treatment). The clinical efficacy,renal function[creatinine(Cr),urea nitrogen(BUN),uric acid(SUA)],toxin removal effect[parathyroid hormone(PTH),blood β2 microglobulin(β2-MG),half a Cystatin C(Cys C)]and the occurrence of adverse reactions were compared between the two groups. Results The total clinical effective rate(95.83%)in the HFHD group was higher than that in the HD group(81.82%),and the difference was statistically significant(P<0.05). After treatment,Cr,BUN and SUA in the two groups decreased,and the decrease was more obvious in the HFHD group,and the difference was statistically significant(P<0.05). After treatment,PTH,β2-MG,Cys C decreased in both groups,and the decrease was more obvious in the HFHD group,and the difference was statistically significant(P<0.05). The incidence of adverse reactions in the HFHD group was 8.33%,which was lower than 25.00% in the HD group,and the difference was statistically significant(P<0.05). Conclusion HFHD in the treatment of patients with chronic renal failure in the uremic stage can effectively improve the clinical efficacy and improve the renal function of the patients.,and reduce the medium and macromolecular toxins in the patients and has good safety.
作者
邱强
宋洁
张月
QIU Qiang;SONG Jie;ZHANG Yue(Department of Nephrology,Shunyi District Hospital,Beijing,China,101312)
出处
《分子诊断与治疗杂志》
2022年第11期1993-1996,共4页
Journal of Molecular Diagnostics and Therapy
基金
北京市卫生科技发展专项基金(2018-7-265)。
